Searchable abstracts of presentations at key conferences on calcified tissues

ba0002p61 | (1) | ICCBH2013

Elevated FGF23 levels in premature infants without excessive phosphaturia

Fatani Tarah , Binjab Asma , Weiler Hope , Sharma Atul , Rodd Celia

Preterm infants develop reduced bone mass and fragility fractures. Nevertheless, normal ranges in preterm infants are poorly defined for concentrations of vitamin D; its isomers (C3α-epimer of 25(OH)D3) and metabolites (24, 25(OH)2D3, 1, 24(OH)2D); and other mineral-regulating hormones, including FGF23 in both intact (iFRG23) and inactive (C- terminal) forms.Objective: To clarify normal concentrations of minerals and hormones in healthy, preterm inf...

ba0002p60 | (1) | ICCBH2013

Failure of free, public vitamin D supplementation program for Quebec infants: temporal trends and significant predictors

Millette Maude , Sharma Atul , Weiler Hope , Sheehy Odile , Berard Anick , Rodd Celia

Over 80% of Quebec woman initiate breastfeeding, and rates of exclusive breastfeeding at 6 months doubled from 2003 (9.7%) to 2009 (19.0%). To prevent deficiency, current recommendations for these infants include 400 IU/day of vitamin D. For 20 years, Quebec has offered a program of free vitamin D supplements through its public medication insurance plan (RAMQ).Objective: Program evaluation over the last decade.Methods: This is a re...

ba0007oc9 | (1) | ICCBH2019

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Ward Leanne M , Alos Nathalie , Cabral David A , Rodd Celia , Sbrocchi Anne Marie , Padidela Raja , Shaw Nick , Kostik Mikhail , Alexeeva Ekaterina , Thandrayen Kebashni , Aftring Paul , Choudhury Anup , Sunkara Gangadhar , Sayyed Sarfaraz , Munns Craig F.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...